Acetyl-L-Carnitine: Benefits, Forms, Dosing, and Side Effects

Acetyl-L-carnitine (ALCAR) is an acetylated form of L-carnitine that crosses the blood-brain barrier more effectively than standard L-carnitine. It has been studied for cognitive decline, Alzheimer's disease, peripheral neuropathy, depression, blood pressure, cardiovascular health, insulin resistance, and male infertility. This article synthesizes clinical trial data from meta-analyses, Cochrane Reviews, and randomized controlled trials — covering every major study on ALCAR with sample sizes, dosages, durations, and effect sizes.

Table of Contents

• Overview
• Forms and Bioavailability
• Evidence for Benefits
• Recommended Dosing
• Dietary Sources
• Safety and Side Effects
• Drug Interactions
• References

Overview

Acetyl-L-carnitine (ALCAR) is an acetylated form of L-carnitine, a naturally occurring compound derived from the amino acids lysine and methionine [1][2]. Carnitine plays a critical role in energy production by transporting long-chain fatty acids into the mitochondria, where they undergo beta-oxidation to produce adenosine triphosphate (ATP) [1][3]. Approximately 95% of total body carnitine is stored in heart and skeletal muscle, with the remainder in the liver, kidneys, and circulating plasma [1][4].

What distinguishes acetyl-L-carnitine from standard L-carnitine is the acetyl group attached at the 3-position oxygen, which increases lipophilicity and allows ALCAR to cross the blood-brain barrier more effectively than L-carnitine [5][6]. This property enables ALCAR to influence central nervous system functions, including neurotransmitter synthesis, mitochondrial energy metabolism in neurons, and neuroprotection [2][5]. ALCAR is believed to play a role in the production of acetylcholine, an important neurotransmitter involved in memory and learning, by donating acetyl groups to choline [7][8].

The body synthesizes carnitine endogenously in the liver, kidneys, and brain. Healthy adults produce approximately 14.4 mg/day, which, combined with dietary intake, is sufficient to meet carnitine needs under normal conditions [1][4]. The Food and Nutrition Board of the National Academies concluded in 1989 that carnitine is not an essential nutrient and did not establish Dietary Reference Intakes (DRIs) [1][9]. However, carnitine becomes conditionally essential under certain conditions, such as premature birth, end-stage renal disease, or genetic transport defects [1][2].

Dietary carnitine has a bioavailability of approximately 63–75% from foods [1][10]. In contrast, absorption of supplemental L-carnitine is substantially lower at 14–18% [1][10]. Unabsorbed carnitine is degraded by microorganisms in the large intestine [11]. The bioavailability of supplemental acetyl-L-carnitine has not been as well studied, though some evidence suggests slightly higher circulating concentrations compared to equivalent L-carnitine doses, with peak plasma levels typically achieved 2–4 hours after oral administration [5][12].

Carnitine status can be assessed by measuring circulating carnitine levels. A plasma free carnitine concentration of 20 mcmol/L or less, or a total carnitine concentration of 30 mcmol/L or less, is considered abnormally low [1]. The ratio of acyl-L-carnitine ester to free L-carnitine (a ratio of 0.4 or greater indicates abnormal metabolism) can also be used [1].

ALCAR has been approved in various countries for indications including cerebrovascular disorders, mental function enhancement, and nutritional supplementation [5]. It is widely available as an over-the-counter dietary supplement, with the global market valued at $58.1 million in 2023, projected to grow to $97.5 million by 2033 [5].

Forms and Bioavailability

Carnitine Forms Comparison

Several forms of carnitine are used in supplements and clinical settings. Each has distinct properties and applications. It is important not to substitute one form for another, as the benefits of each form may depend on the intact molecule or its specific metabolites [11].

Form	Key Properties	Primary Uses
Acetyl-L-Carnitine (ALCAR)	Acetylated form. Crosses blood-brain barrier. Molecular formula C₉H₁₇NO₄ (MW 203.24 g/mol). Oral bioavailability higher than L-carnitine supplements [5][12].	Cognitive decline, neuropathy, depression, blood pressure [2][5][7]
L-Carnitine	Unacetylated form. Oral supplement bioavailability 14–18%. Dietary bioavailability 63–75% [1][10].	Cardiovascular disease, athletic performance, weight loss, dialysis-related deficiency [1][3]
Propionyl-L-Carnitine	Acyl derivative of L-carnitine.	Peripheral artery disease, intermittent claudication, sexual dysfunction [3][13]
L-Carnitine-L-Tartrate	Combined with tartaric acid. NOT found to be more bioavailable than L-carnitine in a study of 5 healthy men [11].	Exercise recovery (marketed, limited evidence)
L-Carnitine Fumarate	Combined with fumaric acid. Lower absorption than L-carnitine [14].	Generally not recommended due to inferior absorption
D-Carnitine	Biologically inactive stereoisomer. Should NOT be used — competes with active L-forms and can cause symptoms of carnitine deficiency [11].	None (contraindicated)

Bioavailability and Absorption

ALCAR is absorbed primarily through the gastrointestinal tract via a combination of active transport and passive diffusion [5][12]. Its acetylated structure enhances absorption compared to L-carnitine supplements, with studies demonstrating a 43% increase in circulating ALCAR concentrations following daily oral doses of 2 g [12]. Peak plasma levels are typically achieved 2–4 hours after oral administration [5][12].

Transport of ALCAR across cell membranes, including the blood-brain barrier, is primarily mediated by the organic cation/carnitine transporter 2 (OCTN2, encoded by SLC22A5), a sodium-dependent transporter expressed on the luminal side of endothelial cells [5]. This transporter exhibits high affinity for ALCAR, enabling efficient delivery to neuronal cells.

ALCAR is eliminated mainly through renal excretion, with the unchanged compound and its metabolites (such as L-carnitine following deacetylation) appearing in urine. Renal reabsorption is efficient at low plasma concentrations but becomes saturated at higher levels, leading to increased clearance. Plasma concentrations return to baseline within 12 hours after intravenous administration of 0.5 g [5][12].

Chemical Stability

Acetyl-L-carnitine is stable in neutral to acidic aqueous solutions (pH below 9) but degrades rapidly at alkaline pH values greater than 9, with significant loss of integrity observed after short exposure times at room temperature [5]. This pH-dependent stability influences handling in pharmaceutical preparations, where acidic or neutral conditions are preferred.

The hydrochloride salt (C₉H₁₈ClNO₄) is the most common commercial form, appearing as a white to off-white crystalline powder with a melting point of approximately 194°C. It exhibits high solubility in water (greater than 100 mg/mL) and ethanol (approximately 20 mg/mL) [5].

Evidence for Benefits

Memory and Cognitive Function

Alzheimer's Disease and Dementia

ALCAR has been one of the most extensively studied dietary supplement ingredients for memory disorders. Its mechanism involves supporting acetylcholine synthesis and helping remove toxic compounds to alleviate mitochondrial dysfunction associated with degeneration of brain structures [2][15].

Montgomery et al. 2003 meta-analysis: A meta-analysis of 21 clinical trials including a total of 1,204 adults with mild cognitive impairment or mild Alzheimer's disease examined the effects of 1.5 to 3.0 g/day acetyl-L-carnitine versus placebo for 3 to 12 months. Clinical and psychometric assessment scores were better, and clinician-determined improvements were greater in supplement users than in placebo groups [16].

Hudson & Tabet 2003 Cochrane Review: A Cochrane Review of 15 clinical trials (including 13 of those in the meta-analysis above) assessed 1 to 3 g/day ALCAR supplementation versus placebo over 12 to 52 weeks in participants with mild to moderate dementia or cognitive decline. The results showed that supplementation decreased symptom severity at 12 and 24 weeks but NOT at 52 weeks. Similarly, ALCAR improved Mini Mental State Examination (MMSE) scores at 24 weeks but not at 12 or 52 weeks. It had no effect on the severity of dementia, functional ability, or overall clinical global impression scores. The authors noted that results from more recent studies were less positive than those from earlier studies, and concluded that routine clinical use of ALCAR to treat dementia signs and symptoms was not justified [15].

Spagnoli et al. 1991 (landmark Italian trial): A double-blind, placebo-controlled trial involving 130 patients with Alzheimer's disease demonstrated that one year of ALCAR treatment resulted in a slower rate of deterioration compared to placebo across 13 of 14 outcome measures, including significant improvements in the Blessed Dementia Scale, logical intelligence, verbal critical abilities, long-term verbal memory, and selective attention [5][17].

Thal et al. 1996 (multicenter trial): A larger multicenter, randomized, double-blind, placebo-controlled study enrolled 431 patients with mild to moderate probable Alzheimer's disease, administering 3 g/day of ALCAR for 12 months. While overall decline rates were similar between groups, post-hoc subgroup analysis indicated slower cognitive decline in early-onset patients (aged 65 or younger) compared to placebo, as measured by the Alzheimer's Disease Assessment Scale cognitive subscale and Clinical Dementia Rating Scale [5][18].

Summary: While early studies found evidence of modest benefit, later and larger studies failed to find ALCAR effective for established dementia [15]. If there is any benefit at all, it may be limited to people with mild cognitive impairment and early Alzheimer's disease, and particularly to younger-onset cases [7][16]. The effects remain an area of active research [2][19][20].

Preclinical Combination Data (ALCAR + Alpha-Lipoic Acid)

Preclinical studies in aged rats have demonstrated that combining ALCAR with alpha-lipoic acid (ALA) synergistically improves cognitive function more effectively than either compound alone. Dietary supplementation restored performance on spatial memory (Morris water maze) and temporal memory tasks, reduced oxidative damage to RNA in the hippocampus, and reversed age-associated mitochondrial structural decay. Similar trends were observed in ApoE4 mouse models relevant to Alzheimer's risk. While direct human trials on the combination for cognition are sparse, the mechanistic synergy supports potential for addressing mitochondrial dysfunction in age-related cognitive decline [5].

Blood Pressure

Acetyl-L-carnitine (500 to 1,000 mg taken twice daily) for a period of months may modestly reduce systolic blood pressure in people with high blood pressure, although it does not appear to lower diastolic blood pressure [7].

Ruggenenti et al. 2009: A study found that taking 1 gram of acetyl-L-carnitine twice daily for 6 months lowered systolic blood pressure by approximately 8 mmHg compared to baseline. However, this study did not include a comparison group, making the results uncertain [7][21].

McMackin et al. 2007: A study in 36 people (average age 63) with coronary artery disease found that taking 500 mg of acetyl-L-carnitine plus 200 mg of alpha-lipoic acid twice daily for 8 weeks lowered systolic blood pressure by 9 mmHg in those with coronary artery disease and high blood pressure, which was significant compared to placebo. The study was partially funded by the maker of the supplement (Juvenon Cellular Health Supplement, Juvenon Inc.) [7][22].

Parvanova et al. 2018 (DIABASI trial): A study in 219 older people with high blood pressure, high cholesterol, and diabetes found that taking 1 gram of acetyl-L-carnitine twice daily for 6 months did NOT lower systolic blood pressure compared to placebo. The participants were taking simvastatin, which can also lower blood pressure and may have overshadowed any effects of acetyl-L-carnitine [7][23]. This trial also observed no significant changes in glycemic control or insulin sensitivity [5].

Insulin sensitivity pilot study (Ruggenenti): A pilot study in nondiabetic subjects at increased cardiovascular risk with insulin resistance found that 2 g/day of oral ALCAR for 6 months improved insulin-mediated glucose disposal (measured by euglycemic hyperinsulinemic clamp) alongside reductions in blood pressure [5][21].

Peripheral Neuropathy

Diabetic Neuropathy

Guidelines from the American Society of Pain and Neuroscience (ASPN) state that, although dietary supplements including acetyl-L-carnitine may have a role in managing painful diabetic neuropathy, there is insufficient high-quality evidence comparing ALCAR to typical pharmacologic drugs, and there is not enough information about safe dosing, to recommend for or against its use [7][24].

Li et al. 2019 meta-analysis: A systematic review and meta-analysis of four randomized controlled trials involving patients with painful peripheral neuropathy found that ALCAR significantly reduced pain by 20.2% (95% CI: 8.3–32.1%, P < 0.0001) relative to baseline on a 10-cm Visual Analog Scale. A subgroup of three RCTs in diabetic peripheral neuropathy showed even greater relief at 24.6% (95% CI: 12.4–36.8%, P < 0.0001). Evidence was graded as Class II (probably effective) per American Academy of Neurology guidelines [5][25].

2019 Cochrane Review: A Cochrane review of RCTs on ALCAR for diabetic peripheral neuropathy concluded very low-certainty evidence (GRADE system) indicating uncertainty regarding short-term pain relief, but noted potential improvements in nerve conduction velocity. It highlighted gaps in long-term data beyond 6–12 months and heterogeneity in dosing protocols [5][26].

Clinical evidence demonstrates that oral doses of 1–3 grams per day, administered for 6–12 months, can reduce neuropathic pain scores, with enhancements in nerve fiber regeneration and sensory function, particularly when combined with standard therapies [5]. Dosing regimens typically start at 500 mg twice daily, titrated up to 1.5–3 grams per day [5].

Antiretroviral-Associated Neuropathy

Youle et al. 2007: A small, multicenter clinical study among 56 people with neuropathy associated with antiretroviral drug therapy showed that receiving 500 mg of acetyl-L-carnitine twice daily intramuscularly for two weeks, followed by 1,000 mg twice daily orally for 6 weeks, reduced pain by 0.89 points (on a 0–10 scale) compared to placebo. However, it did not reduce pain, burning, or numbness based on two other symptom scales [7][27].

Chemotherapy-Induced Neuropathy — CAUTION

Hershman et al. 2018: A double-blind, placebo-controlled study among women receiving taxane-based chemotherapy to treat breast cancer found that 3 grams of acetyl-L-carnitine taken daily for 5.5 months significantly WORSENED symptoms of chemotherapy-induced peripheral neuropathy compared to placebo, and this difference persisted after 2 years [7][28].

Loprinzi et al. 2020 (ASCO guideline): Based on the above evidence, the American Society of Clinical Oncology recommended in 2020 that clinicians DISCOURAGE use of acetyl-L-carnitine for preventing chemotherapy-related nerve damage [29].

Depression

ALCAR shows promise in treating depression, with research dating back to the 1990s highlighting antidepressant-like effects through modulation of neurotransmitter systems [5].

Veronese et al. 2017 meta-analysis: A systematic review and meta-analysis of nine randomized controlled trials showed that ALCAR supplementation significantly decreased depressive symptoms compared to placebo (standardized mean difference −1.10, 95% CI −1.65 to −0.56), with effects comparable to established antidepressants like fluoxetine, particularly in older adults or those with treatment-resistant depression [5][30].

Early studies from the late 1990s reported that supplementation at 1–2 grams per day improved mood and reduced fatigue in patients with major depressive disorder, as evidenced by reductions in Hamilton Depression Rating Scale scores by about 20–30% over 4–8 weeks [5].

Fibromyalgia

Leombruni et al. 2015: A study of 51 people with fibromyalgia (average age 52) compared 500 mg of acetyl-L-carnitine three times daily versus 30 to 60 mg of duloxetine daily. Those given ALCAR did NOT experience an improvement in pain intensity or anxiety compared to baseline. While they showed a 2.18-point improvement (on a 7-point scale) in overall severity of illness and a reduction in depression based on one scale, they did not show improvement in depression based on another scale. Those in the duloxetine group showed similar improvements in depression and no improvement in anxiety, but DID show reduction in pain. Critically, the study lacked a placebo group [7][31].

Chronic Fatigue Syndrome

A 2004 randomized trial demonstrated decreased fatigue severity and improved quality of life metrics in patients with chronic fatigue syndrome after 24 weeks of treatment at 2 grams daily [5][32].

Cardiovascular Disease

Carnitine plays a role in transporting long-chain fatty acids in the myocardial mitochondria for energy production, moderating oxidative stress, and potentially decreasing markers of inflammation. During ischemic events, carnitine prevents fatty acid ester accumulation, which can lead to fatal ventricular arrhythmias [3][33][34].

Acute Myocardial Infarction — DiNicolantonio et al. 2013 meta-analysis: A meta-analysis of 13 clinical trials including 3,629 adults with acute myocardial infarction who took L-carnitine (from 2.7 g/day for 5 days to 6 g/day for 12 months) versus placebo found that L-carnitine significantly reduced rates of all-cause mortality, ventricular arrhythmias, and new-onset angina. However, it did not affect risk of heart failure or myocardial reinfarction [3][33].

Chronic Heart Failure — Song et al. 2017 meta-analysis: A meta-analysis of 17 clinical trials including 1,625 adults with chronic heart failure found that 1–6 g/day L-carnitine supplements for 7 days to 3 years improved left ventricular ejection fraction by 4.14%, stroke volume by 8.21 mL, and cardiac output by 0.88 L/min compared to routine treatment. However, L-carnitine did not affect rates of all-cause mortality or walking test performance [3][35].

TMAO and Cardiovascular Risk — Important Concern: Koeth et al. (2013, Nature Medicine) found that L-carnitine is metabolized by intestinal microbiota to trimethylamine-N-oxide (TMAO), a proatherogenic substance associated with increased CVD risk. In 2,595 adults aged 54–71, omnivorous participants produced more TMAO than vegans or vegetarians after L-carnitine consumption. Dose-dependent associations existed between L-carnitine levels and risk of coronary artery disease, peripheral artery disease, and CVD — but only in participants with concurrently high TMAO levels [3][7][36]. Although ALCAR is not identical to L-carnitine, it contains the same TMA moiety and may potentially foster TMAO-producing organisms [7][36].

Johri et al. 2022 (atherosclerosis RCT): A clinical trial in 157 individuals aged 58–75 with metabolic syndrome who received 1 g L-carnitine or placebo twice daily for 6 months found that total cholesterol and LDL cholesterol levels were higher in participants taking L-carnitine. L-carnitine supplementation was also associated with 9.3% greater carotid arterial plaque stenosis in males who ate less red meat [3][37].

Peripheral Artery Disease — Tama et al. 2021: A systematic review of three RCTs compared 234 participants taking 2 g/day oral propionyl-L-carnitine for 4–6 months with 222 patients on placebo. One trial showed improved peak walking times and decreased pain; the other two showed no benefit [3][38].

Insulin Resistance and Diabetes

Zamani et al. 2023 meta-analysis: A meta-analysis of 41 RCTs examined L-carnitine supplementation in 2,900 adults. L-carnitine supplements at 0.25–4 g/day for 2–52 weeks reduced fasting blood glucose, insulin resistance, and HbA1c but NOT serum insulin levels [3][41].

Xu et al. 2017 meta-analysis: Five RCTs in 631 adults with insulin resistance showed that 2–3 g/day L-carnitine for 4 weeks to 12 months improved insulin resistance, with benefits at 12 months exceeding those at 3 months [3][42].

Vidal-Casariego 2013 meta-analysis: Four RCTs with 284 type 2 diabetes patients showed 2–3 g/day L-carnitine for 12–52 weeks reduced fasting glucose, total cholesterol, LDL cholesterol, and apolipoproteins B100 and A1 but NOT triglycerides, lipoprotein(a), or HbA1c [3][43].

Male Infertility

Salas-Huetos et al. 2018 meta-analysis: Three RCTs examining 1–3 g/day L-carnitine or ALCAR for 2–6 months in 201 men aged 20–40 with infertility found supplemental carnitine improved sperm motility by 7.84% and morphology by 4.91% but did NOT affect sperm concentration [3][46].

de Ligny et al. 2022 Cochrane Review: Six RCTs in 1,089 men with subfertility taking 1,000–3,000 mg/day carnitine for 8 weeks to 6 months found increased sperm motility and concentration at some timepoints but NO effect on live birth or pregnancy rates [3][47].

Mongioi et al. 2020: A systematic review confirmed ALCAR + L-carnitine significantly improved total sperm motility, progressive motility, and morphology at doses of at least 3 g/day, but did not affect sperm concentration or clinical pregnancy rates [5][48].

Female Infertility (PCOS)

Ismail et al. 2014: A 26-month RCT of 170 women <35 with PCOS found clomiphene citrate + 3 g/day L-carnitine resulted in 64.4% higher ovulation rates and thicker endometrial tissue (10.1 mm vs. 6.8 mm) than placebo. More pregnancies and fewer miscarriages occurred in the carnitine group [3][49].

El Sharkwy et al. 2019: A 3-month RCT of 280 women with PCOS found 3 g L-carnitine improved menstrual cycle regularity and ovulation/pregnancy rates, but miscarriage rates did not differ [3][50].

Osteoarthritis

Mahdavi et al. 2016: An RCT in 69 women aged 40–60 with mild-moderate knee osteoarthritis found 250 mg L-carnitine three times daily for 8 weeks reduced inflammation biomarkers and visual analog scale pain by 52.67% versus placebo [3][51].

Baghban et al. 2021: An RCT of 76 women (average age 55) with obesity and knee osteoarthritis found 1 g/day L-carnitine for 12 weeks did NOT reduce pain, stiffness, or improve physical function versus placebo [3][52].

Leg Cramps

High doses of L-carnitine (typically ≥1,500 mg/day) have been used for leg cramps due to carnitine deficiency. Miwa (2020) reported that 1,500 mg/day reduced nocturnal leg cramps post-stroke [7][55]. Imbe et al. (2018) found 600 mg/day reduced cramps in diabetes [7][56]. However, no published clinical trials exist specifically on acetyl-L-carnitine for leg cramps [7].

Athletic Performance

Wall et al. 2011: 14 recreational athletes aged 24–28 consuming 2.0 g L-carnitine tartrate twice daily + carbohydrate for 24 weeks showed reduced perceived exertion (14.0 vs. 16.2, Borg scale) at 50% and 80% VO₂max [3][58].

Novakova et al. 2016: 24 men (8 omnivores, 16 vegetarians) taking 1 g L-carnitine twice daily for 12 weeks showed no effect on VO₂max, lactate, or performance in either group. Skeletal muscle carnitine increased by ~13% in vegetarians only [3][59].

Fielding et al. 2018 (review): 11 trials in 251 athletes (1–4 g/day up to 6 months) and 17 studies in 237 recreationally active adults showed mixed results. Some studies found reduced lactate and improved VO₂max; others found no benefit [3][60].

Mielgo-Ayuso et al. 2021: A systematic review of 11 RCTs in 203 adults found some improvements in VO₂max and peak power, but no studies showed benefit for moderate-intensity exercise [3][61].

Weight Loss

Pooyandjoo et al. 2016 meta-analysis: Nine RCTs in 911 participants found carnitine supplementation resulted in 1.33 kg more weight loss than placebo [3][63]. Villani et al. (2000) found no effect of 2 g/day L-carnitine for 8 weeks in obese women [7][62]. Derosa et al. (2010) found 2 g/day L-carnitine + orlistat for 1 year produced greater weight loss (11.3 vs. 9.5 kg) in type 2 diabetes [3][64].

Other Uses

Androgen decline in older men: ALCAR (2 g) + propionyl-L-carnitine (2 g) daily improves sexual dysfunction, depression, and fatigue [7][11].

Peyronie's disease: 2 g/day for 3 months reduced pain and slowed disease progression (Biagiotti 2001) [7][66].

Eye health: Combination therapy (ALCAR + omega-3 + CoQ10) reduced dry eye symptoms after 3 months [5][67].

Sarcopenia: Preliminary evidence suggests ALCAR may preserve muscle mass and function in the elderly by improving mitochondrial efficiency [5][68].

Fragile X syndrome: Early research suggests ALCAR (20–50 mg/kg/day) may reduce hyperactivity in affected boys [7][11].

Hemodialysis: A meta-analysis (Hurot et al. 2002) found carnitine may help manage anemia but not blood lipids in dialysis patients [3][69].

Recommended Dosing

There is no established Dietary Reference Intake for carnitine. The following dosing ranges are based on clinical trial protocols:

Indication	Dose (Acetyl-L-Carnitine)	Duration
Alzheimer's disease / dementia	1.5–4 g/day, divided into 2–3 doses	3–12 months [7][11]
Age-related memory impairment	1.5–2 g/day	Ongoing [7][11]
Depression in elderly	1.5–3 g/day, divided doses	4–12 weeks [5][7][11]
Blood pressure	1–2 g/day (500–1,000 mg twice daily)	2–6 months [7][21][22]
Diabetic neuropathy	1.5–3 g/day, divided doses	6–12 months [5][7][11]
Antiretroviral neuropathy	1 g twice daily	6–8 weeks [7][27]
Fibromyalgia	1.5 g/day (500 mg × 3)	Variable [7][31]
Male infertility	3–4 g/day (sometimes mixed ALCAR + L-carnitine)	2–6 months [7][11]
Peyronie's disease	2 g/day, divided into 2 doses	3 months [7][66]
Androgen decline (older men)	2 g ALCAR + 2 g propionyl-L-carnitine	Variable [7][11]
Fragile X syndrome (children)	20–50 mg/kg/day	Variable [7][11]
Chronic fatigue syndrome	2 g/day	24 weeks [5][32]
Insulin resistance / diabetes	2–3 g/day (L-carnitine)	4 weeks–12 months [3][41][42]

ALCAR is taken in fairly large doses — often measured in grams rather than milligrams. Doses are typically divided into two or three administrations per day. Doses of approximately 3 g/day or more are associated with increased gastrointestinal side effects [1][11].

Dietary Sources

Carnitine is found primarily in animal products, especially red meat [1][10]. An omnivorous diet provides approximately 24–145 mg carnitine daily, while a vegan diet provides only about 1.2 mg [1]. The body needs approximately 15 mg/day from a combination of dietary sources and endogenous synthesis [1].

Food	Serving	Carnitine (mg)
Beef steak, cooked	3 ounces	42–122
Ground beef, cooked	3 ounces	65–74
Milk, whole	1 cup	8
Codfish, cooked	3 ounces	3–5
Chicken breast, cooked	3 ounces	2–4
Ice cream	½ cup	3
Cheese, cheddar	2 ounces	2
Whole-wheat bread	2 slices	0.2
Asparagus, cooked	½ cup	0.1

Source: NIH Office of Dietary Supplements [1]. Poultry, fish, and dairy provide some carnitine, while vegetables, fruits, and grains provide negligible amounts. A person weighing 165 lb on a strict vegetarian diet synthesizes approximately 14.4 mg/day endogenously, which meets daily needs [1].

Safety and Side Effects

General Safety Profile

Acetyl-L-carnitine is generally considered safe and well-tolerated at recommended doses [5][7]. Carnitine does not have an established tolerable upper intake level [1].

Common Side Effects

• Gastrointestinal: Nausea, vomiting, abdominal cramps, and diarrhea — the most common adverse effects, occurring primarily at doses exceeding 3 g/day [1][5][7].
• Fishy body odor: Carnitine supplementation at approximately 3 g/day can cause urine, breath, and sweat to have a fishy odor [1][7].
• Agitation and restlessness: ALCAR may cause agitation in some users. Mild restlessness and insomnia have been reported, particularly when taken later in the day [5][7].
• Muscle weakness: Can occur in people with uremia [1].
• Seizures: Can potentially increase the number or severity of seizures in those with seizure disorders [1][5].

Populations Requiring Caution

Thyroid disorders: People with low or borderline-low thyroid levels should NOT take ALCAR because it may impair thyroid hormone function. Low thyroid levels are particularly common among women over 60 years of age. Conversely, carnitine may be helpful in cases of hyperthyroidism [7][70].

Chemotherapy patients: ALCAR significantly worsened chemotherapy-induced peripheral neuropathy in a placebo-controlled trial (Hershman et al. 2018). The American Society of Clinical Oncology recommends AGAINST its use for preventing chemotherapy-related nerve damage [28][29].

Seizure disorders: ALCAR has been associated with increased number or severity of seizures, particularly at high doses [1][5].

Renal disease / dialysis: Individuals on dialysis should not take carnitine without physician supervision [7].

TMAO Cardiovascular Concern

Some research suggests that L-carnitine intake may contribute to cardiovascular disease in certain people. People who eat red meat maintain organisms in their gut that digest carnitine to trimethylamine (TMA), a precursor to TMAO, which appears to advance atherosclerosis [7][36]. Vegetarians and vegans do not have this reaction when first exposed to carnitine. Supplementing with ALCAR (which contains the TMA moiety) may potentially foster growth of these organisms and increase TMAO levels, although clinical evidence is mixed [7][36][37].

Hair Loss Concerns

No robust scientific evidence links ALCAR supplementation to hair loss. Studies on related carnitine forms, such as L-carnitine-L-tartrate, actually indicate potential promotion of scalp hair growth. Anecdotal reports of hair loss are often attributable to confounding factors [5].

Drug Interactions

Blood Thinners (Anticoagulants)

ALCAR should be used with caution in people taking blood-thinning medication, as it can theoretically increase the anticoagulant effect, increasing the risk of bruising and bleeding. Regular INR monitoring is recommended when co-administered with warfarin [7][5].

Thyroid Medications

ALCAR may decrease the effectiveness of thyroid hormone by interfering with its activity, potentially necessitating monitoring or dosage adjustments in patients on levothyroxine or similar therapies [5][7][70].

Anticonvulsants (Valproic Acid)

Treatment with valproic acid, phenobarbital, phenytoin, and carbamazepine reduces blood levels of carnitine [1][71][72][73]. Valproic acid may cause hepatotoxicity and increase plasma ammonia, leading to encephalopathy. Intravenous L-carnitine may help treat valproic acid toxicity [1][74][75].

Pivalate-Conjugated Antibiotics

Carnitine interacts with pivalate-conjugated antibiotics such as pivampicillin. Chronic administration can lead to carnitine depletion [1][10][76].

Famotidine (H2 Blockers)

Sato et al. 2025: A retrospective study among 25 adults requiring carnitine replacement therapy showed that those on famotidine were much more likely to have low carnitine levels despite supplementation compared to those not taking famotidine (36.8% vs. 3.9%). Famotidine inhibits a kidney transporter that helps retain carnitine [7][77].

References

1. National Institutes of Health, Office of Dietary Supplements. "Carnitine — Health Professional Fact Sheet." https://ods.od.nih.gov/factsheets/Carnitine-HealthProfessional/

2. Ferreira GC, McKenna MC. "L-carnitine and acetyl-L-carnitine roles and neuroprotection in developing brain." Neurochem Res 2017;42:1661-75. https://pubmed.ncbi.nlm.nih.gov/28508995/

3. National Institutes of Health, Office of Dietary Supplements. "Carnitine — Health Professional Fact Sheet." (Carnitine and Health sections). https://ods.od.nih.gov/factsheets/Carnitine-HealthProfessional/

4. Borum PR. "Carnitine." In: Marriott B, Birt DF, Stalling V, Yates A, eds. Present Knowledge in Nutrition, 11th ed. 2020:551-9.

5. Grokipedia. "Acetyl-L-carnitine." https://grokipedia.com/page/Acetyl-L-carnitine

6. Gnoni A, Longo S, Gnoni GV, Giudetti AM. "Carnitine in human muscle bioenergetics." Molecules 2020;25:182. https://pubmed.ncbi.nlm.nih.gov/31906498/

7. ConsumerLab. "Acetyl-L-Carnitine Supplements Review." https://www.consumerlab.com/reviews/acetyl-l-carnitine-supplements-review/acetyl-l-carnitine/

8. Bianchetti A, Rozzini R, Trabucchi M. "Effects of acetyl-L-carnitine in Alzheimer's disease patients unresponsive to acetylcholinesterase inhibitors." Curr Med Res Opin 2003;19:350-3. https://pubmed.ncbi.nlm.nih.gov/12841930/

9. National Research Council. Food and Nutrition Board. Recommended Dietary Allowances, 10th ed. National Academy Press, 1989.

10. Rebouche CJ. "Kinetics, pharmacokinetics, and regulation of L-carnitine and acetyl-L-carnitine metabolism." Ann NY Acad Sci 2004;1033:30-41.

11. ConsumerLab. "Acetyl-L-Carnitine Supplements Review — ConsumerTips." https://www.consumerlab.com/reviews/acetyl-l-carnitine-supplements-review/acetyl-l-carnitine/

12. Rebouche CJ. "Carnitine." In: Ross AC, et al., eds. Modern Nutrition in Health and Disease, 11th ed. 2014:252-3.

13. Tama B, et al. "Propionyl-L-carnitine in intermittent claudication." Cureus 2021;13:e17592. https://pubmed.ncbi.nlm.nih.gov/34650861/

14. EFSA AFC Panel. "L-carnitine-L-tartrate for use in foods." EFSA J 2003.

15. Hudson S, Tabet N. "Acetyl-L-carnitine for dementia." Cochrane Database Syst Rev 2003;2003(2):CD003158. https://pubmed.ncbi.nlm.nih.gov/12804452/

16. Montgomery SA, Thal LJ, Amrein R. "Meta-analysis of ALCAR vs placebo in MCI and mild Alzheimer's." Int Clin Psychopharmacol 2003;18:61-71. https://pubmed.ncbi.nlm.nih.gov/12598816/

17. Spagnoli A, et al. "Long-term acetyl-L-carnitine treatment in Alzheimer's disease." Neurology 1991;41(11):1726-32.

18. Thal LJ, et al. "A 1-year multicenter placebo-controlled study of ALCAR in Alzheimer's disease." Neurology 1996;47(3):705-11.

19. Pennisi M, et al. "Acetyl-L-carnitine in dementia: a critical update." Nutrients 2020;12:1389. https://pubmed.ncbi.nlm.nih.gov/32408706/

20. Lodeiro M, et al. "Decreased CSF L-carnitine in early Alzheimer's disease." J Alzheimers Dis 2014;41:223-32. https://pubmed.ncbi.nlm.nih.gov/24577479/

21. Ruggenenti P, et al. "Ameliorating hypertension and insulin resistance: effects of ALCAR therapy." Hypertension 2009;54(3):567-74.

22. McMackin CJ, et al. "Alpha-lipoic acid and ALCAR on vascular function and blood pressure." J Clin Hypertens 2007;9(4):249-55.

23. Parvanova A, et al. "DIABASI trial." J Endocr Soc 2018.

24. Sayed D, et al. "ASPN guideline for painful diabetic neuropathy." J Pain Res 2024.

25. Li S, et al. "ALCAR for peripheral neuropathic pain: systematic review and meta-analysis." J Pain Res 2019.

26. Cochrane Review. "ALCAR for diabetic peripheral neuropathy." 2019.

27. Youle M, et al. "ALCAR for antiretroviral toxic neuropathy." HIV Med 2007.

28. Hershman DL, et al. "ALCAR for prevention of taxane-induced neuropathy." J Clin Oncol 2018;36(20):2048-55.

29. Loprinzi CL, et al. "ASCO guideline: chemotherapy-induced peripheral neuropathy." J Clin Oncol 2020;38(28):3325-48.

30. Veronese N, et al. "ALCAR and depressive symptoms: systematic review and meta-analysis." Psychosom Med 2018;80:154-9.

31. Leombruni P, et al. "Duloxetine vs ALCAR in fibromyalgia." Clin Exp Rheumatol 2015;33(1 Suppl 88):S82-5.

32. Vermeulen RCW, Scholte HR. "Acetyl- and propionyl-carnitine in chronic fatigue syndrome." Psychosom Med 2004;66(2):276-82.

33. DiNicolantonio JJ, et al. "L-carnitine in secondary prevention of CVD: meta-analysis." Mayo Clin Proc 2013;88:544-51. https://pubmed.ncbi.nlm.nih.gov/23597877/

34. Oyanagi E, et al. "Protective action of L-carnitine on mitochondrial function." Biochem Biophys Res Commun 2011;412:61-7.

35. Song X, et al. "L-carnitine for chronic heart failure: meta-analysis." Biomed Res Int 2017;2017:6274854. https://pubmed.ncbi.nlm.nih.gov/28497060/

36. Koeth RA, et al. "Intestinal microbiota metabolism of L-carnitine promotes atherosclerosis." Nat Med 2013;19:576-85. https://pubmed.ncbi.nlm.nih.gov/23563705/

37. Johri AM, et al. "Atherosclerosis progression with carnitine supplementation." Nutr Metab (Lond) 2022;19:26. https://pubmed.ncbi.nlm.nih.gov/35365175/

38. Tama B, et al. "Propionyl-L-carnitine for intermittent claudication." Cureus 2021;13:e17592. https://pubmed.ncbi.nlm.nih.gov/34650861/

39. Sangwung P, et al. "Mitochondrial dysfunction and insulin resistance." Endocrinology 2020;161:bqaa017. https://pubmed.ncbi.nlm.nih.gov/32060541/

40. Yazici D, Sezer H. "Insulin resistance, obesity and lipotoxicity." Adv Exp Med Biol 2017;960:277-304. https://pubmed.ncbi.nlm.nih.gov/28585204/

41. Zamani M, et al. "L-carnitine and glycemic markers: systematic review and meta-analysis." Front Nutr 2023;9:1082097. https://pubmed.ncbi.nlm.nih.gov/36698467/

42. Xu Y, et al. "L-carnitine for insulin resistance: meta-analysis." Adv Clin Exp Med 2017;26:333-8. https://pubmed.ncbi.nlm.nih.gov/28791854/

43. Vidal-Casariego A. "L-carnitine and type 2 diabetes: meta-analysis." Exp Clin Endocrinol Diabetes 2013;121:5. https://pubmed.ncbi.nlm.nih.gov/23147210/

44. Skoracka K, et al. "Diet and male (in)fertility." J Clin Med 2020;9:1400. https://pubmed.ncbi.nlm.nih.gov/32397541/

45. Agarwal A, et al. "L-carnitine in female infertility." Reprod Biol Endocrinol 2018;16:5. https://pubmed.ncbi.nlm.nih.gov/29373970/

46. Salas-Huetos A, et al. "Nutrients and sperm quality: meta-analysis." Adv Nutr 2018;9:833-48. https://pubmed.ncbi.nlm.nih.gov/30462179/

47. de Ligny W, et al. "Antioxidants for male subfertility." Cochrane Database Syst Rev 2022;5:CD007411. https://pubmed.ncbi.nlm.nih.gov/35506389/

48. Mongioi LM, et al. "Carnitine in male infertility." Andrology 2020.

49. Ismail AM, et al. "L-carnitine + clomiphene in PCOS: RCT." Eur J Obstet Gynecol Reprod Biol 2014;180:148-52. https://pubmed.ncbi.nlm.nih.gov/25015747/

50. El Sharkwy I, et al. "L-carnitine + metformin in PCOS." Gynecol Endocrinol 2019;35:701-5. https://pubmed.ncbi.nlm.nih.gov/30810434/

51. Mahdavi AM, et al. "L-carnitine in knee osteoarthritis." J Am Coll Nutr 2016;35:597-603. https://pubmed.ncbi.nlm.nih.gov/26923508/

52. Baghban F, et al. "L-carnitine in obese women with knee osteoarthritis." BMC Musculoskelet Disord 2021;22:195. https://pubmed.ncbi.nlm.nih.gov/33607984/

53. Takahashi M, et al. "L-carnitine for nocturnal leg cramps." Physiol Rep 2021.

54. Nakanishi H, et al. "L-carnitine and muscle cramps in cirrhosis." Clin Gastroenterol Hepatol 2015.

55. Miwa H. "L-carnitine for nocturnal leg cramps after stroke." Nutrition 2020.

56. Imbe A, et al. "L-carnitine for leg cramps in diabetes." Endocr J 2018.

57. Peeling P, et al. "Evidence-based supplements for athletic performance." Int J Sport Nutr Exerc Metab 2018;28:178-87. https://pubmed.ncbi.nlm.nih.gov/29345167/

58. Wall BT, et al. "L-carnitine + carbohydrate and muscle fuel metabolism." J Physiol 2011;589:963-73. https://pubmed.ncbi.nlm.nih.gov/21224234/

59. Novakova K, et al. "L-carnitine in male vegetarians." Eur J Nutr 2016;55:207-17. https://pubmed.ncbi.nlm.nih.gov/25612929/

60. Fielding R, et al. "L-carnitine in recovery after exercise." Nutrients 2018;10:349. https://pubmed.ncbi.nlm.nih.gov/29534031/

61. Mielgo-Ayuso J, et al. "L-carnitine and exercise intensity: systematic review." Nutrients 2021;13:4359. https://pubmed.ncbi.nlm.nih.gov/34959937/

62. Villani RG, et al. "L-carnitine does not promote weight loss." Int J Sport Nutr Exerc Metab 2000;10:199-207.

63. Pooyandjoo M, et al. "L-carnitine and weight loss: meta-analysis." Obes Rev 2016;17:970-6. https://pubmed.ncbi.nlm.nih.gov/27335245/

64. Derosa G, et al. "Orlistat + L-carnitine in obese diabetic patients." Endocr J 2010;57:777-86. https://pubmed.ncbi.nlm.nih.gov/20683172/

65. Derosa G, et al. "L-carnitine and lipoprotein(a) in type 2 diabetes." Clin Ther 2003;25:1429-39. https://pubmed.ncbi.nlm.nih.gov/12867218/

66. Biagiotti G, Cavallini G. "ALCAR vs tamoxifen in Peyronie's disease." BJU Int 2001;88:63-7.

67. Combination therapy studies for dry eye (ALCAR + omega-3 + CoQ10). Various clinical observations.

68. Malaguarnera M, et al. "L-carnitine reduces fatigue and improves cognition in centenarians." Am J Clin Nutr 2007;86(6):1738-44.

69. Hurot JM, et al. "L-carnitine in hemodialysis: systematic review." J Am Soc Nephrol 2002;13:708-14. https://pubmed.ncbi.nlm.nih.gov/11856775/

70. Benvenga S, et al. "L-carnitine as peripheral antagonist of thyroid hormone." Ann NY Acad Sci 2004.

71. Hug G, et al. "Serum carnitine reduction during anticonvulsant therapy." J Pediatr 1991;119:799-802.

72. Castro-Gago M, et al. "Carnitine levels in epileptic children." J Child Neurol 1998;13:546-9.

73. Verrotti A, et al. "Carnitine deficiency with valproic acid." Int J Clin Lab Res 1999;29:36-40.

74. Lheureux PE, Hantson P. "Carnitine for valproic acid toxicity." Clin Toxicol 2009;47:101-11.

75. Perrott J, et al. "L-carnitine for valproic acid overdose: systematic review." Ann Pharmacother 2010;44:1287-93.

76. Brass EP. "Pivalate-generating prodrugs and carnitine homeostasis." Pharmacol Rev 2002;54:589-98.

77. Sato K, et al. "Famotidine and carnitine levels." Pharmazie 2025.